Opening New Pathways for Respiratory and Chronic Disease Patients

Via Precision Inhaled Drug Delivery

At Aerami Therapeutics, we leverage our proprietary inhalation technology to develop differentiated inhaled therapies for the treatment of severe respiratory and other chronic diseases.

AER-901

Inhaled Imatinib for Pulmonary Arterial Hypertension

A drug-device combination product candidate in Phase 1 for the treatment of pulmonary arterial hypertension

AER-501

Human Inhaled Insulin for Type 1 and 2 Diabetes

A soft mist inhaled human insulin for the treatment of Type 1 and 2 diabetes

AER-601

Inhaled GLP-1 for Type 2 Diabetes

An inhaled glucagon-like peptide-1 (GLP-1) analog for Type 2 diabetes

Commitment That’s Easy to Take In

Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the development of differentiated inhaled therapies for the treatment of severe respiratory and other chronic diseases.

About Our Company